Cell Line Data Sheet for CHLA-90

Disease:	Neuroblastoma
Phase of Therapy:	Post-Chemotherapy (Progressive Disease), Post-bone marrow transplant
Treatment:	Cisplatin, cyclophosphamide, doxorubicin, etoposide, melphalan, teniposide, total body irradiation
Disease Stage:	4
Gender:	Male
Age at diagnosis:	102 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Bone marrow
Primary Tumor Site:	N/A
Date Established:	1990
MYCN Patient:	Non-amplified
MYCN Cell line:	N/A
TH mRNA:	Expressed
p53 functionality:	Non-functional
Telomere Mechanism:	N/A
ALK:	F1245V
RNAseq:	N/A
WES:	N/A
Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO_2, 20% O_2, 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	59 hours
Growth Properties:	Flat, epithelial-like cells with processes
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	The repository has a matching EBV lymphoblastoid cell line – COG-V-499.

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis

Cell Line Data Sheet for CHLA-90

Cell Line Name: **CHLA-90**
References:

1. Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Res. 61:6185-6193, 2001. PubMed ID: 11507071
   https://cancerres.aacrjournals.org/content/61/16/6185.long

2. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 58:5396-5405, 1998 PubMed ID: 9850071
   https://cancerres.aacrjournals.org/content/58/23/5396.long

3. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemoth Pharm. 45: 1-8, 2000. PubMed ID: 10647494
   https://link.springer.com/article/10.1007%2FPL00006736

4. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. Cancer Res. 61, 679-686, 2001. PubMed ID: 11212268
   https://cancerres.aacrjournals.org/content/61/2/679.long

5. Yang B, Reynolds CP: Tirapazamine cytotoxicity for neuroblastoma is p53-dependent. Clin Cancer Res. 11:2774-2780, 2005. PubMed ID: 15814660
   https://clincancerres.aacrjournals.org/content/11/7/2774.long

6. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 6:886-89, 2007. PubMed ID: 17363483
   https://mct.aacrjournals.org/content/6/3/886.long

7. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clin Cancer Res. 13:3079-3086, 2007. PubMed ID: 17505011
   https://clincancerres.aacrjournals.org/content/13/10/3079.long

8. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr Blood Cancer. 56: 239-249, 2011. PubMed ID: 20922763 (www.PPTPinvitro.org)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

9. J. L. Rokita, K. S. Rathi, M. F. Cardenas, K. A. Upton, J. Jayaseelan, K. L. Cross, J. Pfeil, L. E. Egolf, G. P. Way, A. Farrel, N. M. Kendsersky, K. Patel, K. S. Gaonkar, A. Modi, E. R. Berko, G. Lopez, Z. Vaksman, C. Mayoh, J. Nance, K. McCoy, M. Haber, K. Evans, H. McCalmont, K. Bendak, J. W. Böhm, G. M. Marshall, V. Tyrrell, K. Kalletla, F. K. Braun, L. Qi, Y. Du, H. Zhang, H. B. Lindsay, S. Zhao, J. Shu, P. Baxter, C. Morton, D. Kurmashev, S. Zheng, Y. Chen, J. Bowen, A. C. Bryan, K. M. Leraas, S. E. Coppens, H. Doddapaneni, Z. Momin, W. Zhang, G. I. Sacks, L. S. Hart, K. Krytska, Y. P. Mosse, G. J. Gatto, Y. Sanchez, C. S. Greene, S. J. Diskin, O. M. Vaske, D. Haussler, J. M. Gastier-Foster, E. A. Kolb, R. Gorlick, X. N. Li, C. P. Reynolds, R. T. Kurmasheva, P. J. Houghton, M. A. Smith, R. B. Lock, P. Raman, D. A. Wheeler, J. M. Maris, Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019;29:1675-1689.e1679. PMID: 31693904

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880934/

10. B. Koneru, G. Lopez,A170:E170 A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani, M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020;80:2663-2675." PMID 32291317
https://cancerres.aacrjournals.org/content/80/12/2663.long

Cell Line Data Sheet for CHLA-90

Cell Line Name: **CHLA-90**

(10x magnification)



(10x magnification)



(20x magnification)



(20x magnification)